Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, closed its thirteenth fund, at $450 million.
With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients.
Atlas Venture collaborates with experienced venture partners and entrepreneurs-in-residence to found, seed, incubate, and invest in new biotech startups. Taking a global view of scientific innovation, Atlas-backed companies are formed from breakthrough discoveries and technologies from institutions and researchers around the world. Atlas-built companies are shaped according to the unique scientific opportunity of each, resulting in a mix of platform and asset-centric companies, all focused on the goal of creating transformational new medicines.
The firm has been building and investing in innovative biotech startups for more than two decades. Since 2015, Atlas Venture has raised over $2 billion and has created and/or invested in over 50 biotech companies.
In addition to Fund XIII, Atlas is also investing from Opportunity Fund II, a $300 million fund raised in 2021 to support portfolio companies as they raise subsequent financings and advance therapeutic programs. The investing partners in Fund XIII include Jason Rhodes, Kevin Bitterman, Bruce Booth, Jean-François Formela, Michael Gladstone, and David Grayzel.
FinSMEs
03/03/2022